16/04/2023 - 18/04/2023, 6:00 am-6:00 pm - Barcelona, Spain
The European Heart Rhythm Association (EHRA) Congress will be held from 16-18 April 2023. EHRA is the leading European EP conference and brings together scientists, healthcare professionals and key opinion leaders involved in arrhythmia management from all around the world.
Website: https://www.escardio.org/Congresses-&-Events/EHRA-Congress
AtriCure at EHRA 2023 – Improving Lives for the Most Complex Arrhythmia Patients
Join us at EHRA 2023 in Barcelona to discover the latest evidence and techniques for the treatment of AF with Hybrid AF™ Therapies. During the 20th EHRA edition, you will have the opportunity to join top-class educational programs on how Hybrid AF™ Therapies can address unmet clinical needs in complex AF treatment, as well as gain hands-on experience on “Epicardial Options for Arrhythmia Ablation” in the EHRA Simulation Village. AtriCure is also scheduling an invitation-only event to display the latest prototypes and innovation projects in the field of electrophysiology. We also invite you to visit the AtriCure event booth C500 to learn more about AtriCure therapies and programs.
Innovation Suite – Sunday 16 April from 18:00 to 20:00
In this educational event, you will be able to discover the latest technologies for Hybrid AF™ Therapies, learn about future developments, and explore how our innovative devices and therapies could be considered for the treatment of the most complex arrhythmias, including Atrial Fibrillation, Ventricular Tachycardia, Inappropriate Sinus Tachycardia and Brugada Syndrome.
This event is upon invitation only, please contact your AtriCure representative to attend.
Venue: Hotel Santos Porta Fira Barcelona
Plaza Europa, 45 08908 Hospitalet de Llobregat, Spain
CEASE-AF trial results
To be presented in the Late Breaking Science – Day 2 session
Monday 17 April
14:00 / Lecture room 1
Join the Late Breaking Science session to hear the Principal Investigators disclosing the CEASE-AF Efficacy and Safety Endpoints results. CEASE-AF is a perspective, multicenter, randomized trial comparing the efficacy and safety of Hybrid Total Thoracoscopic Ablation Therapy vs standard catheter ablation, in preventing the recurrence of AF in symptomatic, drug refractory patients with persistent or longstanding persistent AF.
Chairpersons:
Pierre Jais (University of Bordeaux – Bordeaux, France)
Serge Boveda (Clinic Pasteur – Toulouse, France)
14: 00 CEASE AF: Primary Efficacy and Safety Endpoints – Nicolas Doll (Schüchtermann Klinik, Bad Rothenfelde, Germany)
14:10 CEASE AF: Primary Efficacy and Safety Endpoints – Discussion – Stylianos Tzeis (Athens, Greece)
Expo Booth
Come and meet us at our booth located at C500.
Symposium – CME Accredited Program
Sunday 16 April from 15:45 to 16:30
in Lecture Room 3 / Channel 3
Hybrid Ablation: AF and Beyond
Organised by Radcliffe Medical Education, supported by an unrestricted educational grant from AtriCure. Program:
– Chair’s welcome – Harry Crijns, Maastricht, NL
– Which arrhythmias could benefit from a hybrid approach? – Carlo De Asmundis, Brussels, BE
– Hybrid ablation in IST: A case study – Mark La Meir, Brussels, BE
– What can we learn from persistent and long-standing persistent AF? – Ashley Nisbet, Bristol, UK
– Panel discussion and audience Q&A – All, moderated by Harry Crijns, Maastricht, NL
– Close – Harry Crijns, Maastricht, NL
EHRA Simulation Village: Epicardial Options for Arrhythmia Ablation
Learning Objectives:
– Improve your understanding of Hybrid AF™ Therapies
– Discover how the combination of Epicardial and Endocardial ablation techniques can be used to treat several arrhythmias, including AF, VTs, IST and Brugada Syndrome
– Explore different techniques and approaches using AtriCure’s innovative beating heart simulation model
| Sunday 16 April 08:30 – 09:30 10:45 – 11:45 14:30 – 15:30 16:45 – 17:45 |
Monday 17 April 08:30 – 09:30 10:45 – 11:45 14:30 – 15:30 16:45 – 17:45 |
Tuesday 18 April 08:30 – 09:30 12:00 – 13:00 |